Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 18/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | CALML3 | P27482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174998 | 0.91 | GRM2 (0.71) | GRM2HTR2ACALML3 | |
| SCHEMBL3858607 | 0.84 | GRM2 (0.73) | GRM2HTR2ACALML3 | |
| SCHEMBL3875961 | 0.74 | GRM2 (0.61) | GRM2HTR2ACALML3 | |
| SCHEMBL3859804 | 0.71 | GRM2 (0.77) | GRM2HTR2A | |
| SCHEMBL15757524 | 0.71 | GRM2 (0.60) | GRM2HTR2ACALML3 | |
| SCHEMBL2827150 | 0.68 | GRM2 (0.66) | GRM2HTR2A | |
| SCHEMBL4176048 | 0.68 | GRM2 (0.75) | GRM2HTR2A | |
| SCHEMBL26280841 | 0.66 | L3MBTL1 (0.52) | GRM2 | |
| SCHEMBL26280845 | 0.66 | L3MBTL1 (0.52) | GRM2 | |
| SCHEMBL3869934 | 0.66 | GRM2 (1.00) | GRM2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009004430-A1 | N-BENZYL OXAZOLIDINONES AND RELATED HETEROCYCLEIC COMPOUNDS AS POTENTIATORS OF GLUTAMATE RECEPTORS | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885HTR2A 599/4885CALML3 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.